SPRINTER LONG - PHARMING GROUP | Market Closed - Euronext Paris 11:30:00 2024-05-10 am EDT | ||
| 0.128 EUR | +8.47% |
|
| Current month | +10.34% | ||
| 1 month | -54.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
PHARMING GROUP N.V.
Latest news about PHARMING GROUP N.V.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.128 | +8.47% | 31 |
| 24-05-09 | 0.118 | -10.61% | 32 |
| 24-05-08 | 0.132 | -7.04% | 67 |
| 24-05-07 | 0.142 | -2.74% | 26 |
| 24-05-06 | 0.146 | -2.67% | 32 |
Real-time Euronext Paris
Last update May 10, 2024 at 11:30 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | PHARMING GROUP N.V. |
| Issuer | ING Bank |
| B3J7G | |
| ISIN | NLING0017F49 |
| Date issued | 2022-08-10 |
| Strike | 0.7943 € |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.707 € |
|---|---|
| Lowest since issue | 0.11 € |
Company Profile
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
Sector
-
Consensus: Pharming Group N.V.
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.882
EUR
Average target price
1.933
EUR
Spread / Average Target
+119.20%
- Stock Market
- Certificates
- B3J7G Certificat